Clinical trial NCT02618538 - References

Breast Cancer — The Andromeda Study.Predictive Value of Combined Criteria to Tailor Breast Cancer Screening.

Citation(s)

•   Giorgi D, Giordano L, Ventura L, Frigerio A, Paci E, Zappa M
  [Mammography breast cancer screening in Italy: 2010 survey]. Epidemiol Prev. 2012 Nov-Dec;36(6 Suppl 1):8-27. Italian.
•   Godfrey AC, Xu Z, Weinberg CR, Getts RC, Wade PA, DeRoo LA, Sandler DP, Taylor JA
  Serum microRNA expression as an early marker for breast cancer risk in prospectively collected samples from the Sister Study cohort. Breast Cancer Res. 2013 May 24;15(3):R42. doi: 10.1186/bcr3428.
•   Ng EK, Li R, Shin VY, Jin HC, Leung CP, Ma ES, Pang R, Chua D, Chu KM, Law WL, Law SY, Poon RT, Kwong A
  Circulating microRNAs as specific biomarkers for breast cancer detection. PLoS One. 2013;8(1):e53141. doi: 10.1371/journal.pone.0053141. Epub 2013 Jan 3.
•   Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD
  Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst. 2008 Oct 15;100(20):1432-8. doi: 10.1093/jnci/djn326. Epub 2008 Oct 7.
•   Petracci E, Decarli A, Schairer C, Pfeiffer RM, Pee D, Masala G, Palli D, Gail MH
  Risk factor modification and projections of absolute breast cancer risk. J Natl Cancer Inst. 2011 Jul 6;103(13):1037-48. doi: 10.1093/jnci/djr172. Epub 2011 Jun 24.
•   Schousboe JT, Kerlikowske K, Loh A, Cummings SR
  Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness. Ann Intern Med. 2011 Jul 5;155(1):10-20. doi: 10.7326/0003-4819-155-1-201107050-00003.
•   Sozzi G, Boeri M, Rossi M, Verri C, Suatoni P, Bravi F, Roz L, Conte D, Grassi M, Sverzellati N, Marchiano A, Negri E, La Vecchia C, Pastorino U
  Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. J Clin Oncol. 2014 Mar 10;32(8):768-73. doi: 10.1200/JCO.2013.50.4357. Epub 2014 Jan 13. Erratum in: J Clin Oncol. 2014 May 10;32(14):1520.
•   Vilaprinyo E, Forné C, Carles M, Sala M, Pla R, Castells X, Domingo L, Rue M; Interval Cancer (INCA) Study Group
  Cost-effectiveness and harm-benefit analyses of risk-based screening strategies for breast cancer. PLoS One. 2014 Feb 3;9(2):e86858. doi: 10.1371/journal.pone.0086858. eCollection 2014.
•   Wu Q, Wang C, Lu Z, Guo L, Ge Q
  Analysis of serum genome-wide microRNAs for breast cancer detection. Clin Chim Acta. 2012 Jul 11;413(13-14):1058-65. doi: 10.1016/j.cca.2012.02.016. Epub 2012 Feb 23.

Predictive Value of Combined Criteria to Tailor Breast Cancer Screening and New Opportunities From Circulating Markers. The Andromeda Study.

Details for clinical trial NCT02618538